# A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).

> **NCT05156229** · PHASE1 · TERMINATED · sponsor: **Codiak BioSciences** · enrollment: 2 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma (CTCL)

## Interventions

- **BIOLOGICAL:** CDK-003

## Key facts

- **NCT ID:** NCT05156229
- **Lead sponsor:** Codiak BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-06
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-08-24
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety profile. Proceeding to Phase II did not require additional data from this Phase I Dose-Finding study.
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156229, "A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05156229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*